Short answer
PHIBRO ANIMAL HEALTH CORP (PAHC) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $387M (up 6.3% year over year) with net income of $30M.
Q3 2026 key financials · XBRL
- Revenue
- $387M
- +6.3% YoY
- Net income
- $30M
- +11.3% YoY
- Operating margin
- 12.8%
- Gross margin
- 33.2%
- EPS (diluted)
- $0.72
- +10.8% YoY
Source: XBRL data from the PHIBRO ANIMAL HEALTH CORP (PAHC) Q3 2026 10-Q on SEC EDGAR. USD.
PHIBRO ANIMAL HEALTH CORP Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $386.8M, up 6% YoY from $363.9M, driven by Mineral Nutrition and Animal Health
- Gross margin 33.2% vs 32.9% YoY, operating margin 12.8% vs 14.1%, net margin 7.6% vs 7.3%
- Best segment Mineral Nutrition: revenue $73.6M, up 17%; worst Vaccines: revenue $39.5M, down 2%
- Operating cash flow $26.1M vs $9.3M; capital expenditures $18.8M; dividends $4.9M
- Near-term liquidity expected adequate for 12 months; Brazil virginiamycin sales fell $5.2M amid regulatory restrictions and tariff risks remain
Risk Factors
- No material changes in risk factors from the Annual Report
- Regulatory and compliance exposure: risks disclosed in the Annual Report remain applicable
- Operational and market exposure: business and future results remain subject to Annual Report risks
- Financial condition exposure: Annual Report risks could materially affect financial condition
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PHIBRO ANIMAL HEALTH CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.